195514-80-8
中文名稱(chēng)
AP 20187
英文名稱(chēng)
AP20187
CAS
195514-80-8
分子式
C82H107N5O20
分子量
1482.75
MOL 文件
195514-80-8.mol
更新日期
2024/12/27 11:28:31
195514-80-8 結(jié)構(gòu)式
基本信息
中文別名
化合物AP20187 英文別名
AP20187B/B Homodimerizer
AP20187 (AP-20187
AP20187
AP-20187
AP 20187
(1R,1'R)-(((((2-((dimethylamino)methyl)propane-1,3-diyl)bis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy))bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl) (2S,2'S)-bis(1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate)
(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[[2-[[[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]methyl]-3-(dimethylamino)propyl]amino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate
所屬類(lèi)別
生物化工：激動(dòng)劑抑制劑物理化學(xué)性質(zhì)
沸點(diǎn)1333.5±65.0 °C(Predicted)
密度1.192±0.06 g/cm3(Predicted)
儲(chǔ)存條件Store at -20°C,protect from light
溶解度≥74.14 mg/mL in DMSO; ≥100 mg/mL in EtOH
酸度系數(shù)(pKa)13.97±0.46(Predicted)
形態(tài)固體
顏色White to yellow
AP 20187價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-13992 | AP 20187 AP20187 | 195514-80-8 | 1mg | 1080元 |
| 2024/11/08 | HY-13992 | AP 20187 AP20187 | 195514-80-8 | 5mg | 2700元 |
| 2024/11/08 | HY-13992 | AP 20187 AP20187 | 195514-80-8 | 10mg | 4300元 |
常見(jiàn)問(wèn)題列表
生物活性
AP20187 (B/B Homodimerizer) 是一種細(xì)胞滲透性分子，使 FK506 結(jié)合蛋白 (FKBP) 二聚化，啟動(dòng)生物信號(hào)傳導(dǎo)級(jí)聯(lián)反應(yīng)和基因表達(dá)，或破壞蛋白-蛋白之間相互作用。靶點(diǎn)
FKBP homodimerizer
體外研究
When LNCaP cells are treated with AP20187 (B/B Homodimerizer) (100 nM), ro-iCaspase-9 levels are significantly reduced, and the smaller processed active caspase-9 becomes apparent.
體內(nèi)研究
Real-time PCR analysis shows that AP20187 (B/B Homodimerizer) (0.5 mg/kg, 2 mg/kg, or 5 mg/kg) treatment significantly increases the levels of CHOP mRNA in the CNS of PLP/Fv2E-PERK mice at PID12. AP20187 treatment significantly alleviates EAE-induced myelin damage in these mice. AP20187 (B/B Homodimerizer) treatment significantly reduces the number of degenerating axons and increases the density of axons in the demyelinating lesions in the lumbar spinal cord of PLP/Fv2E-PERK mice.